AR042244A1 - Vector de expresion, procedimiento para la preparacion de productos genicos heterologos y procedimiento de seleccion para celulas recombinantes de alta produccion - Google Patents
Vector de expresion, procedimiento para la preparacion de productos genicos heterologos y procedimiento de seleccion para celulas recombinantes de alta produccionInfo
- Publication number
- AR042244A1 AR042244A1 ARP030104395A ARP030104395A AR042244A1 AR 042244 A1 AR042244 A1 AR 042244A1 AR P030104395 A ARP030104395 A AR P030104395A AR P030104395 A ARP030104395 A AR P030104395A AR 042244 A1 AR042244 A1 AR 042244A1
- Authority
- AR
- Argentina
- Prior art keywords
- expression vector
- procedure
- cells
- preparation
- products
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
- C12N15/69—Increasing the copy number of the vector
Landscapes
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10256083A DE10256083A1 (de) | 2002-11-29 | 2002-11-29 | Expressionsvektor, Verfahren zur Herstellung von heterologen Genprodukten und Selektionsverfahren für hochproduzierende rekombinante Zellen |
Publications (1)
Publication Number | Publication Date |
---|---|
AR042244A1 true AR042244A1 (es) | 2005-06-15 |
Family
ID=32403676
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP030104395A AR042244A1 (es) | 2002-11-29 | 2003-11-28 | Vector de expresion, procedimiento para la preparacion de productos genicos heterologos y procedimiento de seleccion para celulas recombinantes de alta produccion |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1567648A1 (zh) |
JP (1) | JP2006507829A (zh) |
KR (1) | KR100820035B1 (zh) |
CN (1) | CN1717486A (zh) |
AR (1) | AR042244A1 (zh) |
AU (1) | AU2003292102A1 (zh) |
BR (1) | BR0316510A (zh) |
CA (1) | CA2507714A1 (zh) |
DE (1) | DE10256083A1 (zh) |
MX (1) | MXPA05005482A (zh) |
TW (1) | TWI321152B (zh) |
WO (1) | WO2004050879A1 (zh) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080124760A1 (en) * | 2006-07-26 | 2008-05-29 | Barbara Enenkel | Regulatory Nucleic Acid Elements |
BRPI0821311B1 (pt) * | 2007-12-21 | 2018-09-18 | Novartis Ag | Ácido nucleico de vetor linearizado, método para produção de uma célula hospedeira de mamífero compreendendo o referido ácido, e método para produção de um polipetídeode interesse |
EP2401377B1 (en) | 2009-02-27 | 2016-05-18 | Novartis AG | Expression vector system comprising two selection markers |
KR101239495B1 (ko) * | 2011-01-21 | 2013-03-05 | 경상대학교산학협력단 | αΑ-크리스탈린 유전자를 발현하는 재조합 아데노바이러스 및 이를 이용한 망막혈관 질환의 유전자 치료 |
JP6014029B2 (ja) * | 2011-05-25 | 2016-10-25 | 国立大学法人 岡山大学 | Reic発現アデノウイルスベクター |
FR2981946B1 (fr) * | 2011-10-28 | 2015-02-20 | Lfb Biotechnologies | Unites de transcription et leur utilisation dans des vecteurs d'expression (yb2/0) |
AU2014297966B2 (en) | 2013-07-31 | 2017-10-26 | Novartis Ag | Novel selection vectors and methods of selecting eukaryotic host cells |
CN104404072B (zh) * | 2014-11-24 | 2018-04-27 | 浙江大学 | 用标记基因预测外源基因表达量及筛选转基因家蚕的方法 |
CN106442685B (zh) * | 2016-10-25 | 2019-03-26 | 山东大学 | 一种快速低成本筛选蛋白质表达条件的方法 |
JP2021530225A (ja) * | 2018-07-13 | 2021-11-11 | ロンザ リミテッドLonza Limited | 内因性タンパク質のレベルを低下させることによって生物学的産物の産生を改善する方法 |
US20220243222A1 (en) * | 2019-05-07 | 2022-08-04 | Amgen Inc. | Vectors and expression systems for producing recombinant proteins |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5179017A (en) * | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4656134A (en) * | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
EP0173552B1 (en) | 1984-08-24 | 1991-10-09 | The Upjohn Company | Recombinant dna compounds and the expression of polypeptides such as tpa |
US5491084A (en) * | 1993-09-10 | 1996-02-13 | The Trustees Of Columbia University In The City Of New York | Uses of green-fluorescent protein |
US6146826A (en) * | 1993-09-10 | 2000-11-14 | The Trustees Of Columbia University In The City Of New York | Green fluorescent protein |
DE19539493A1 (de) * | 1995-10-24 | 1997-04-30 | Thomae Gmbh Dr K | Starker homologer Promotor aus Hamster |
WO1998032869A1 (en) * | 1997-01-29 | 1998-07-30 | Neurosearch A/S | Expression vectors and methods for in vivo expression of therapeutic polypeptides |
WO2001004306A1 (en) * | 1999-07-12 | 2001-01-18 | Genentech, Inc. | Expression vectors and methods |
EP1258255A1 (en) * | 2001-05-18 | 2002-11-20 | Boehringer Ingelheim International GmbH | Conjugates of an antibody to CD44 and a maytansinoid |
-
2002
- 2002-11-29 DE DE10256083A patent/DE10256083A1/de not_active Ceased
-
2003
- 2003-11-25 WO PCT/EP2003/013225 patent/WO2004050879A1/de active Application Filing
- 2003-11-25 KR KR1020057009693A patent/KR100820035B1/ko not_active IP Right Cessation
- 2003-11-25 BR BR0316510-8A patent/BR0316510A/pt not_active Expired - Fee Related
- 2003-11-25 AU AU2003292102A patent/AU2003292102A1/en not_active Abandoned
- 2003-11-25 CN CNA2003801044261A patent/CN1717486A/zh active Pending
- 2003-11-25 CA CA002507714A patent/CA2507714A1/en not_active Abandoned
- 2003-11-25 JP JP2004556182A patent/JP2006507829A/ja active Pending
- 2003-11-25 EP EP03767642A patent/EP1567648A1/de not_active Withdrawn
- 2003-11-25 MX MXPA05005482A patent/MXPA05005482A/es not_active Application Discontinuation
- 2003-11-26 TW TW092133164A patent/TWI321152B/zh not_active IP Right Cessation
- 2003-11-28 AR ARP030104395A patent/AR042244A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
MXPA05005482A (es) | 2005-07-25 |
BR0316510A (pt) | 2005-10-04 |
AU2003292102A1 (en) | 2004-06-23 |
WO2004050879A1 (de) | 2004-06-17 |
TW200502388A (en) | 2005-01-16 |
KR20050085203A (ko) | 2005-08-29 |
CA2507714A1 (en) | 2004-06-17 |
KR100820035B1 (ko) | 2008-04-10 |
DE10256083A1 (de) | 2004-08-12 |
JP2006507829A (ja) | 2006-03-09 |
CN1717486A (zh) | 2006-01-04 |
TWI321152B (en) | 2010-03-01 |
EP1567648A1 (de) | 2005-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR042244A1 (es) | Vector de expresion, procedimiento para la preparacion de productos genicos heterologos y procedimiento de seleccion para celulas recombinantes de alta produccion | |
US20210095323A1 (en) | Method of producing biologically active vitamin k dependent proteins by recombinant methods | |
Kaufman et al. | Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells. | |
EP0574402B2 (en) | Expression of pace in host cells and methods of use thereof | |
ES2266159T3 (es) | Mejora de la galactosilacion de glicoproteinas recombinantes. | |
AR018023A1 (es) | Procedimiento para la fabricacion de polipeptidos con glicosilacion apropiada | |
EP1127154B1 (en) | Method for the production of fvii | |
BRPI0607119A2 (pt) | construção de ácido nucleico, população de construções de ácido nucleico, seqüência promotora quimérica isolada purificada, partìculas revestidas, receptáculo de dosagem para um dispositivo de liberação mediada por partìcula, dispositivo de liberação mediada por partìcula, composição farmacêutica, composição de vacina, e, método in vitro de obter a expressão em células de mamìfero de um polipeptìdeo da influenza de interesse | |
BR0316525A (pt) | Genes de fosfotransferase de neomicina e processos para seleção de células recombinantes de alta produtividade | |
ATE380822T1 (de) | Funf-helix protein | |
ATE342275T1 (de) | Vorübergehend-immortalisierte zellen zur verwendung in gentherapie | |
Parcq et al. | Molecular requirements for safer generation of thrombolytics by bioengineering the tissue-type plasminogen activator A chain | |
Khorshidi et al. | Functional expression of the human coagulation factor IX using heterologous signal peptide and propeptide sequences in mammalian cell line | |
WO2004084838A3 (en) | Identification, quantification, and characterization of t cells and t cell antigens | |
Zhou et al. | Presentation of cytosolic antigens via MHC class II molecules | |
US9587008B2 (en) | Method of producing recombinant vitamin K dependent proteins | |
Satoh et al. | Stable production of recombinant pro-urokinase by human lymphoblastoid Namalwa KJM-1 cells: host-cell dependency of the expressed-protein stability | |
Demasi et al. | Enhanced Proteolytic processing of recombinant human coagulation factor VIII B-domain variants by recombinant Furins | |
Rosnoblet et al. | Regulated von Willebrand factor (vWf) secretion is restored by pro-vWf expression in a transfectable endothelial cell line | |
Bahrami et al. | Production of recombinant human factor IX by propeptide modification in Drosophila S2 cell line | |
Fitzgerald et al. | Umbilical cord endothelial cells expressing large T antigen: comparison with primary cultures and effect of cell age | |
AU2013211534B2 (en) | Method of producing biologically active vitamin K dependent proteins by recombinant methods | |
BAR-SHAVIT et al. | Departments zyxwvutsrqponm | |
AU2016200807A1 (en) | Method of producing biologically active vitamin K dependent proteins by recombinant methods | |
Bischof et al. | The Bloom Syndrome Protein BLM Is Selectively Cleaved during Apoptotic Cell Death |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |